Introduction: The treatment of Helicobacter pylori ( H. pylori ) requires the combination of antibiotic therapy with an antisecretory agent. Due to increasing antibiotic resistance, which varies from one geographical region to another, several eradication protocols exist. Objective: T he o bjective is evaluate and compare the efficacy of three treatment regimens for H. pylori infection: 1) Arm A: Omeprazole + Amoxicillin + Clarithromycin for 10 days; 2) Arm B: Omeprazole + Amoxicillin + Metronidazole for 10 days; 3) Arm C: Sequential treatment = Omeprazole + Amoxicillin for 5 days then Omeprazole + Clarithromycin + Metronidazole for 5 days. Patients and Method: This was a prospective randomised study conducted from February 2016 to July 2016 and from April 2017 to September 2017 in the digestive endoscopy cen ter of the gastroenterology and hepatology department of the University Hospital Center Aristide Le Dantec. Our study population consisted of all patients aged 18 years or older referred for upper GI endoscopy. We included all patients whose indication for the examination was epigastralgia and/or dyspepsia and whose rapid urease test was positive. Patients were randomized to the different treatment arms. A 13C-urea breath test was performed at least 4 weeks after stopping antibiotics and 2 weeks after stopping proton pump inhibitor (PPI). Results: We included 120 patients. There were 95 women and 25 men. The mean age was 40 years. Epigastralgia and dyspepsia were present in 90% and 59% of cases, respectively. Upper GI endoscopy showed peptic ulcer in 19.2% and gastroduodenal erosions in 42.5%. The distribution of patients in the different treatment arms was as follows: 40 patients in arm A, 39 patients in arm B and 41 patients in arm C. Treatment was effective in 71.7% of cases in all arms mixed up. Arms A, B and C were effective in 92.5%, 28.2% and 92.7% of cases respectively. The efficacy of arms A and C was like and greater than that of arm B. Conclusion: The therapeutic strategy for H. pylori must consider the local microbiological and ecological environment. Clarithromycin triple therapy and sequential treatment represent effective protocols in our patients.
De Korwin, J.D. and Bretagne, J.F. (2003) Avantages et inconvénients des différentes méthodes diagnostiques de l’infection a Helicobacter pylori. EMC Gastroentérologie Clinique et Biologique, 27, 380-390.
De Korwin, J.D. and Lehours, P. (2010) Helicobacter pylori: Notions Fondamentales, épidémiologie, méthodes diagnostiques. EMC Gastroentérologie Clinique et Biologique, 9, 1-16. https://doi.org/10.1016/S1155-1968(10)50083-X
Hassan, M.N., Arif, A., Shahzad, M.S., et al. (2020) Global Prevalence of Helicobacter pylori and Its Effects on Human Health. PAB, 9, 936-948. https://doi.org/10.19045/bspab.2020.90098
Diouf, M.L., Ondélé Ipongo, A.P., Dia, D., et al. (2011) évolution de la prévalence des ulcères gastroduodénaux dans le centre d’endoscopie digestive de l’hôpital Aristide Le Dantec de Dakar. JAHG, 5, 23-27. https://doi.org/10.1007/s12157-010-0236-4
Dia, D., Seck, A., Mbengue, M., et al. (2010) Helicobacter pylori et pathologie gastroduodénale a Dakar (Sénégal). Medecine Tropicale, 70, 367-370.
Charles, W. (2006) In Vitro Susceptibility Testing versus in Vivo Effectiveness. Medical Clinics of North America, 90, 1077-1088. https://doi.org/10.1016/j.mcna.2006.07.003
Courillon-Mallet, A. (2005) Résistance de Helicobacter pylori: Chez qui s’acharner et comment? FMC HGE. Post’U; Arch: 33-40. https://www.fmcgastro.org/postu-main/archives/postu-2005-paris/resistance-de-helicobacter-pylori-chez-qui-s’acharner-et-comment
Malfertheiner, P., Megraud, F., O’Morain, C., et al. (2007) The European Helicobacter Study Group. Current Concepts in the Management of Helicobacter pylori Infection—The Maastricht III Consensus Report. Gut, 56, 772-781. https://doi.org/10.1136/gut.2006.101634
Abuhammour, A., Dajani, A., Nounou, M., et al. (2016) Standard Triple Therapy versus Sequential Therapy for Eradication of Helicobacter pylori in Treatment Naïve and Retreat Patients. Arab Journal of Gastroenterology, 17, 131-136. https://doi.org/10.1016/j.ajg.2016.07.001
Benajah, D.A., et al. (2012) Le traitement séquentiel est supérieur à la trithérapie standard dans l’éradication d’Helicobacter pylori chez les patients naïfs au traitement: Résultats d’une étude prospective randomnisée HPFEZ.FMC HGE. Post’U; Arch (CO.54). https://www.fmcgastro.org/postu-main/archives/best-of-2012/le-traitement-sequentiel-est-superieur-a-la-tritherapie-standard-dans-l’eradication-d’helicobacter-pylori-chez-les-patients-naifs-au-traitement-resultats-d’une-etude-prospect
Antibiotics
Resistances
Fock, K.M., Katelaris, S.K., et al. (2009) Second Asia-Pacific Consensus Guidelines for Helicobacter pylori Infection. Journal of Gastroenterology and Hepatology, 24, 1587-1600. https://doi.org/10.1111/j.1440-1746.2009.05982.x
Seck, A., Burucoa, C., Dia, D., et al. (2013) Primary Antibiotic Resistance and Associated Mechanisms in Helicobacter pylori Isolates from Senegalese Patients. Annals Clinical Microbiology Antimicrobials, 12, 3-6. https://doi.org/10.1186/1476-0711-12-3
Fall, F., Diagne, A., Ndiaye, B., et al. (2011) Tritherapie par omeprazole, amoxicilline et clarithromycine dans la maladie ulcereuse duodenale associee a Helicobacter pylori au Senegal. JAHG, 5, 28-32. https://doi.org/10.1007/s12157-010-0237-z
Bensaada, R., Bouani, B., Soussi, Y., et al. (2019) Ulcère à Helicobacter pylori: Efficacité du traitement et facteurs influençant la guérison. Le Pharmacien Hospitalier et Clinicien, 54, 342-347. https://doi.org/10.1016/j.phclin.2019.07.007
Doffou, A.S., Attia, K., Bathaix, M., et al. (2015) The Helicobacter pylori Eradication Rate in a High Prevalence Area (West Africa): Three Triple Therapy Comparative Study. Open Journal of Gastroenterology, 5, 200-206. https://doi.org/10.4236/ojgas.2015.512030
Delchier, J.C. and Parsonnet, J. (2020) Efficacy of a Tailored PCR-Guided Triple Therapy in the Treatment of Helicobacter pylori Infection. Médecine et Maladies Infectieuses, 50, 492-499. https://doi.org/10.1016/j.medmal.2019.06.001
Chang, Y.W., Ko, W.J., et al. (2019) Clarithromycin Resistance and Female Gender Affect Helicobacter pylori Eradication Failure in Chronic Gastritis. The Korean Journal of Internal Medicine, 34, 1022-1029. https://doi.org/10.3904/kjim.2018.054
Hu, Y., Zhu, H., Lu, N., et al. (2017) Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology, 7, 2-22. https://doi.org/10.3389/fcimb.2017.00168
Paoluzi, O.A., Visconti, E., Andrei, F., et al. (2010) Ten and Eight-Day Sequential Therapy in Comparison to Standard Triple Therapy for Eradicating Helicobacter pylori Infection: A Randomized Controlled Study on Efficacy and Tolerability. Journal of Clinical Gastroenterology, 44, 261-266. https://doi.org/10.1097/MCG.0b013e3181acebef
Zullo, A., Rinaldi, V., Winn, P., et al. (2000) A New Highly Effective Short-Term Therapy Schedule for Helicobacter pylori Eradication. Alimentary Pharmacology & Therapeutics, 14, 715-718. https://doi.org/10.1046/j.1365-2036.2000.00766.x
Megraud, F., Coenen, S., Versporten, A., et al. (2013) Helicobacter pylori Resistance to Antibiotics in Europe and Its Relationship to Antibiotic Consumption. Gut, 62, 34-42. https://doi.org/10.1136/gutjnl-2012-302254
Adachi, T., Matsui, S., Watanabe, T., et al. (2017) Comparative Study of Clarithromycin versus Metronidazole Based Triple Therapy as First-Line Eradication for Helicobacter pylori. Oncology, 93, 15-19. https://doi.org/10.1159/000481224
Gisbert, J.P., Calvet, X., O’Connor, A., et al. (2010) Sequential Therapy for Helicobacter pylori Eradication: A Critical Review. Journal of Clinical Gastroenterology, 44, 313-325. https://doi.org/10.1097/MCG.0b013e3181c8a1a3
Lawson-Ananissoh, L., Bouglouga, O., Bagny, A., et al. (2015) Profil épidémiologique des ulcères gastro-duodénaux au centre hospitalier et universitaire Campus de Lomé (Togo). Journal Africain d’Hépato-Gastroentérologie, 9, 99-103. https://doi.org/10.1007/s12157-015-0597-5
Olusoji, A., Ajayi, A.O., Adegum, P.T., et al. (2015) Effectiveness of Triple Therapy Regimens in the Eradication of Helicobacter pylori in Patients with Uninvestigated Dyspepsia in Ekiti State, Nigeria. BJMM, 6, 278-285. https://doi.org/10.9734/BJMMR/2015/14103
Khalife, H., Ghssein, G., et al. (2017) Epidemiology of Helicobacter pylori Infection among the Healthy Population in Lebanon. World Journal of Pharmaceutical Sciences, 6, 363-372. https://doi.org/10.20959/wjpps20176-9298
Lee, H.J., Kim, J., Lee, J.S., et al. (2015) Concomitant Therapy Achieved the Best Eradication Rate for Helicobacter pylori among Various Treatment Strategies. World Journal of Gastroenterology, 21, 351-359.
Seher, C., Thierfelder, W., Dortschy, R., et al. (2000) Helicobacter pylori: Pravalenz in der deutschen Bevolkerung. Gesundheitswesen, 62, 598-603. https://doi.org/10.1055/s-2000-13047
Lahbabi, M., Alaoui, S., El Rhazi, K., et al. (2013) Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication: Result of the HPFEZ Randomised Study. Clinics and Research in Hepatology and Gastroenterology, 37, 416-421. https://doi.org/10.1016/j.clinre.2012.10.002
Hong, W., Tang, H., Dong, X., et al. (2019) Prevalence of Helicobacter pylori Infection in a Third-Tier Chinese City: Relationship with Gender, Age, Birth-Year and Survey Years. Microbiota in Health and Disease, 1, 1-12.
Attia, K.A., Fall, F. and Njoya, O. (2019) Guide de Prise en Charge de la dyspepsie fonctionnelle en Afrique. Médecine d’Afrique Noire, 1, 1-84.